Sweden’s Karo Healthcare is enhancing its OTC offering by acquiring the global rights to topical antifungal brand Lamisil from Haleon for £235m ($299m). The deal – which excludes manufacturing sites and personnel – is expected to close in the fourth quarter.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?